Geistlich Pharma has entered an exclusive national distribution collaboration agreement with StimLabs in the US, focusing on the commercialisation of the former’s Advanced Wound Matrix, Derma-Gide.

Derma-Gide is a 510k cleared, porcine-derived solution for both acute and chronic wounds. It is claimed to be processed using proprietary technologies and is specifically indicated for wound management.

The product's “unique” design characteristics are claimed to be tailored to support healthcare providers with ease of use and handling.

Geistlich Pharma has “expertise” in transforming source tissues into an advanced design with precise characteristics that aid in wound healing.

Geistlich CEO Diego Gabathuler said: “Geistlich is very pleased to have StimLabs as an exclusive distribution partner of Derma-Gide in the US and is looking forward to supporting our joint success moving forward.

“With Derma-Gide, now listed as covered in the recently published US Centers for Medicare & Medicaid Services’ (CMS) local coverage determination (LCD) for diabetic foot ulcers (DFUs), StimLabs will leverage their national channel to support clinicians in the adoption and utilisation of this highly differentiated technology. And we are excited to offer our Advanced Wound Matrix to patients suffering from difficult-to-heal wounds.”

Derma-Gide features a bi-layered design that closely resembles the structural organisation of human skin, promoting re-epithelialisation and cell ingrowth.

The integrated structure of the product is a result of the refinement process, with both layers mechanically linked to create a durable and user-friendly solution.

The upper compact layer of the Advanced Wound Matrix emulates the skin’s basement membrane, facilitating keratinocyte migration and growth factor preservation.

It also offers protection to the wound site and can be sutured if necessary. The lower porous layer is structured to support the modulation of matrix metalloproteinases (MMP) activity, which supports the formation of a physiological extracellular matrix.

This layer can absorb up to nine times its weight in wound fluids, providing an optimal environment for cell migration, attachment, and vascularisation.

StimLabs CEO John Daniel said: “We look forward to working with Geistlich, a trusted global leader in regenerative technologies and are pleased to add a high quality, clinically proven xenograft option to our portfolio."

The matrix is a dual-sourced product, meaning it is derived from two different porcine tissues, each selected for their unique properties that contribute to the product's refinement. While the specific tissues used are protected as trade secrets and not disclosed publicly, the company stated they are neither small intestine submucosa nor dermis.